Latexin facilitates neointimal formation via promoting smooth muscle cell proliferation and macrophage migration

Kyosuke Kazama,Wennan Liu,Zhi-Fu Guo,Xiujuan Zhang,Chen Zhang,Ross Summer,Jianxin Sun

DOI: https://doi.org/10.1101/2024.10.03.616555

2024-10-04

Abstract:Rationale: Neointimal formation is the major cause of cardiovascular diseases such as atherosclerosis and restenosis. Although restenosis rates are significantly reduced by the development of drug-eluting, the stent may not be implanted at all atherosclerotic sites, and long-term dual anti-platelet therapy is needed after stent implantation. Thus, it is essential to elucidate the detailed mechanisms underlying neointimal formation for developing novel therapies. Latexin (LXN), a previously identified pro-inflammatory protein, is highly expressed in vasculature and its expression is regulated by shear stress. Whether it plays a role in vascular remodeling, however, remains unknown. Objective: To determine whether LXN is involved in neointimal formation, and if so, to define the molecular mechanisms involved. Methods and Results: We found that the expression of LXN was significantly increased in neointimal hyperplasia, as determined by western blot. Immunofluorescent staining indicated that increased LXN expression was predominantly localized in smooth muscle cells and macrophages. To determine the cell specific roles of LXN in neointimal formation after injury, we generated global, smooth muscle cell (SMC)-specific, endothelial specific-, and myeloid-specific LXN knockout (KO) mice. We found that global, SMC-, and myeloid-specific LXN deficiency markedly prevented neointimal hyperplasia in mice after carotid artery ligation, whereas LXN deficiency in endothelial cells had no effects. Mechanistically, we found that LXN deficiency in SMCs significantly attenuated SMC proliferation and migration, mainly through inhibiting the expression of platelet-derived growth factor (PDGF) receptors. Intriguely, LXN deficiency in macrophages inhibited monocyte chemoattractant protein-1 (MCP-1)-induced macrophage migration through inhibiting ERK phosphorylation. Conclusions: In summary, we for the first time demonstrated that LXN is essentially involved in SMC proliferation and microphage migration. Specific inhibition of LXN signaling may provide a novel therapeutic strategy for the treatment of cardiovascular diseases, such as restenosis and atherosclerosis.

Physiology